An AI-powered primary diagnostic solution for breast cancer diagnosis, accredited with CE marking.
Biomarkers detection
- Invasive & In Situ Carcinoma
- Mitoses
- Calcifications
- Metastasis
Interested in Cleo Breast?
Improve your workflow with an AI solution that you can trust.
Cleo Breast is an all-in-one AI powered primary diagnostic solution accredited with CE marking. We collaborated with European reference laboratories for clinical use in automated detection and quantification of tumor biomarkers in breast tissue.
Cleo Breast is designed to detect presence or absence of dedicated biomarkers of breast tissue lesions, based on numerized image analysis of histological Whole Slide Image (WSI or digitized slides of histological tissue samples).
Cleo breast provides pathologists and laboratory experts with an automatic and efficient reading of breast cancer diagnosis fully integrated in the laboratory workflow, able to to fully integrate with the laboratory machines.
Cleo Breast is intended to be used as an aid to diagnosis and its results must be reviewed by accredited doctors.
Features
Biomarkers detection
Invasive & In Situ Carcinoma
Detects with high precision the Invasive Carcinoma & In Situ Carcinoma regions and displays the result with a heatmap.
Mitosis
Detects every mitosis object and mitosis hotspots in thecarcinoma regions. The algorithm performs also an automatic mitosis counting.
Calcifications
Detects every potential calcification object. Some calcifications tiles are displayed to help the pathologist to perform a faster analysis.
Metastasis
Detects the macrometastasis regions on lymph nodes slides displayed with a heatmap.
Features
Slides priorization
Cleo Breast automatically prioritizes the most critical cases thanks to a first read analysis and gives you access to a smart work list.
Features
Measurements
Cleo Breast measures the dimensions of the tumors at any point.
First-Read Tool
Vendors agnostic & interoperable
All-in-one platform
Data protection*
*Cleo does not collect any personal data. Our activities are rigorously supervised in accordance with the general data protection regulation (GDPR). All data stay within your personal network.
Our Research work
Features coming soon.
TILs
Our automated TILs scoring tool, leveraging advanced protocols and WHO's recommendations, delivers precise TILs scores for Her2 positive and Triple Negative breast cancer.
Nuclear Atypia
In order to complete the SBR grade and mitosis algorithm, the physician will have access to nuclear atypia analysis.
IHC
Cleo Breast will enable automatic quantification of the following antibodies: Ki67, RE/RP & HER2.
Physicians will have immediate access to the percentage of labeled cells on the entire slide.
Companioning more than 45 users
Julien Adam
HEAD OF PATHOLOGY - SAINT JOSEPH HOSPITAL
Sophie Prévot
MCUPH - APHP
Interested in
Cleo Breast?
Improve your workflow with an AI solution that you can trust.
Already Trusted By
